Loading
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Latest filing published 07 Aug 2026 for Braveheart Bio, Inc., €1.3M. Read the official filing
Filing timeline
BuySaleChristopher Viehbacher
Insider track record
Disclosed buys
1
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
No signal scores available.
Christopher Viehbacher: trading record in brief
Filings by Christopher Viehbacher span 2 companies, the busiest being Biogen Inc. and Braveheart Bio, Inc. The record holds 4 filings, for trades running from 7 February 2025 to 7 August 2026.
No open-market sale appears; the market trades are 1 purchase worth €1.3M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 3 option exercises. In 2026 alone, the filings show 1 purchase and no sales.
The newest entry dates from 7 August 2026: an open-market purchase of €1.3M, in Braveheart Bio, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Christopher Viehbacher
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations4 total
83,333 shares@ US$18.00Common StockSEC:0001470831-26-000801:0
Canonical exit: 5 Nov 2026 (T+90)
9,008 shares0Common StockSEC:0000875045-26-000024:0
7,040 shares0Common StockSEC:0000875045-25-000052:0
9,008 shares0Common StockSEC:0001127602-25-003962:0
4 of 4 declarations
